Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12517
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPremaratne, Eroshaen
dc.contributor.authorVerma, Sen
dc.contributor.authorEkinci, Elif Ien
dc.contributor.authorTheverkalam, Gen
dc.contributor.authorJerums, Georgeen
dc.contributor.authorMacIsaac, Richard Jen
dc.date.accessioned2015-05-16T02:13:30Z
dc.date.available2015-05-16T02:13:30Z
dc.date.issued2014-11-18en
dc.identifier.citationDiabetes & Metabolism 2014; 41(1): 5-17en
dc.identifier.govdoc25457474en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12517en
dc.description.abstractMore than two decades ago, hyperfiltration (HF) in diabetes was postulated to be a maladaptive response observed early in the course of diabetic kidney disease (DKD), which may eventually predispose to irreversible damage to nephrons and development of progressive renal disease. Despite this, the potential mechanisms leading to renal HF in diabetes are not fully understood, although several hypotheses have been proposed, including alterations in glomerular haemodynamic function and tubulo-glomerular feedback. Furthermore, the role of HF as a causative factor in renal disease progression is still unclear and warrants further prospective longer-term studies. Although HF has been entrenched as the first stage in the classic albuminuric pathway to end-stage renal disease in DKD, and HF has been shown to predict the progression of albuminuria in many, but not all studies, the concept that HF predisposes to the development of chronic kidney disease (CKD) stage 3, that is, glomerular filtration rate (GFR) decline to<60mL/min/1.73m(2), remains to be proved. Further long-term studies of GFR gradients therefore are required to establish whether HF ultimately leads to decreased kidney function, after adjustment for glycaemic control and other confounders. Whether reversal of HF with therapeutic agents is protective against reducing the risk of development of albuminuria and renal impairment is also worth investigating in prospective randomized trials.en
dc.language.isoenen
dc.subject.otherDiabetic kidney diseaseen
dc.subject.otherDiabetic nephropathyen
dc.subject.otherHyperfiltrationen
dc.subject.otherMetabolic syndromeen
dc.subject.otherObesityen
dc.subject.otherVascular diseaseen
dc.titleThe impact of hyperfiltration on the diabetic kidney.en
dc.typeJournal Articleen
dc.identifier.journaltitleDiabetes & metabolismen
dc.identifier.affiliationMenzies Institute of Health Research, Darwin, Northern Territory, Australiaen
dc.identifier.affiliationEndocrine Centre & Department of Medicine, Austin Health & University of Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartments of Endocrinology & Diabetes and Medicine, St Vincent's Hospital Melbourne & University of Melbourne, Victoria, Australiaen
dc.identifier.doi10.1016/j.diabet.2014.10.003en
dc.description.pages5-17en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/25457474en
dc.type.austinJournal Articleen
local.name.researcherEkinci, Elif I
item.languageiso639-1en-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptEndocrinology-
crisitem.author.deptEndocrinology-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

42
checked on May 11, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.